Dilapan-S Versus Double Balloon Catheter (CRB) for Preinduction of Labor at Term

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorUniversity of Roma La Sapienza

About this trial

Induction of labor (IOL) is a frequently performed procedure in obstetrics, aimed to achieve vaginal delivery when continuing the pregnancy is no longer advisable. A key determinant of IOL success is cervical ripening, particularly when the cervix is initially unfavorable. A range of preinduction methods is available, encompassing both mechanical and pharmacological approaches. Among mechanical techniques, the double balloon catheter (CRB) facilitates cervical dilation by applying direct pressure, which stimulates local prostaglandin release. In contrast, Dilapan-S, a synthetic osmotic dilator, works by gradually expanding through the absorption of cervical fluids, thereby applying gentle mechanical pressure.

While both methods are widely used and generally considered safe, there is limited evidence directly comparing their effectiveness and patient-centered outcomes. Mechanical methods are associated with a lower risk of uterine hyperstimulation compared to pharmacological alternatives. The choice between CRB and Dilapan-S may significantly influence labor duration, cesarean delivery rates, maternal comfort, and hospital resource utilization. This study aims to fill the existing knowledge gap by directly comparing Dilapan-S and CRB for term preinduction, with a focus on clinical efficacy and maternal satisfaction.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

• Singleton pregnancy

Cephalic fetal presentation

Gestational age ≥ 37+0 weeks

Indication for labor induction (e.g., postdates, maternal hypertension)

Disqualifiers

• Premature rupture of membranes (PROM)

Placenta previa, vasa previa, or abnormal placentation

Active genital tract infection

Prior classical cesarean section or extensive uterine surgery

Trial design

Design model

Parallel

Treatments tested in this trial

  • Higroscopic Cervical ripening

    Device

    Participants assigned to the Dilapan-S group will have 3 to 5 rods inserted under aseptic conditions. Placement will follow manufacturer instructions, and rods will remain in place for up to 12 hours unless spontaneous labor or device expulsion occurs earlier. Upon removal, cervical status will be assessed, and induction will continue with prostaglandins or oxytocin based on standard care.

  • Cervical ripening via CRB

    Device

    Double Balloon Catheter (CRB) Participants randomized to CRB will undergo insertion of a double balloon catheter with inflation of each balloon (approximately 80 mL saline each) according to established protocols. The catheter will remain for up to 12 hours or until spontaneous labor or expulsion. Post-removal management will mirror that of the Dilapan-S group.

Treatment groups

126 Participants
are divided into 2 treatment groups
Group A: Dilapan-SExperimental treatment 1 intervention
Group B: Double Balloon Catheter (CRB)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Time from initiation of cervical ripening to time of delivery measure in hours and minutes

Time frame
from the time of beginning of cervical ripening to the time of delivery measure in hours and minutes

Secondary outcomes

1

Change in Bishop score after device removal

Bishop score scaled from 0 to 10 (higher values indicated better cervical ripening)

Time frame
From the time of beggining of cervical ripening to the time of removal of the device (CRB or dilapan S) 12 hours
2

Mode of delivery

spontaneous vaginal delivery, operative vaginal delivery, emergency cesarean delivery

Time frame
at the time of delivery
3

Need for additional ripening agent

after the removal of CRB or dilapanS needs of using misoprol or dinoprostone to complete cervical ripening

Time frame
From removal of CRB or dilapanS to 96 hours after enrollment
4

Maternal discomfort assessed by VAS

Pain was assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores represent worse outcomes.

Time frame
from CRB insertion or DilapanS removal (12 hours)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: